Atrial Fibrillation and Renal Disease.
作者信息
Berkowitsch Alexander, Wójcik Maciej, Zaltsberg Sergey, Pajitnev Dmitri, Erkapic Damir, Schmitt Joern, Hamm Christian, Kuniss Malte, Neumann Thomas
机构信息
Kerckhoff Heart Center, Bad Nauheim, Germany.
Medical University of Lublin, Lublin, Poland.
出版信息
J Atr Fibrillation. 2013 Aug 31;6(2):837. doi: 10.4022/jafib.837. eCollection 2013 Aug-Sep.
Abstract
Co-incidence of atrial fibrillation and renal dysfunction in general population is described in many epidemiological studies. Major issue is optimal anticoagulation in patients with atrial fibrillation and renal disease warranting balance between risks of ischemic stroke and hemorrhages. The second issue is catheter ablation of AF patients with renal dysfunction. Both issues are discussed in this paper.
摘要
相似文献
1
Atrial Fibrillation and Renal Disease.
J Atr Fibrillation. 2013 Aug 31;6(2):837. doi: 10.4022/jafib.837. eCollection 2013 Aug-Sep.
2
Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.
3
Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
Circ Arrhythm Electrophysiol. 2013 Oct;6(5):868-74. doi: 10.1161/CIRCEP.113.000869. Epub 2013 Sep 18.
4
Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry.
Arch Cardiovasc Dis. 2019 Jun-Jul;112(6-7):420-429. doi: 10.1016/j.acvd.2019.02.006. Epub 2019 May 25.
5
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.
6
Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation.
J Cardiovasc Electrophysiol. 2018 Jun;29(6):823-832. doi: 10.1111/jce.13476. Epub 2018 Mar 30.
7
Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
J Am Heart Assoc. 2015 May 21;4(5):e001901. doi: 10.1161/JAHA.115.001901.
8
Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.
Eur Heart J. 2015 Feb 1;36(5):297-306. doi: 10.1093/eurheartj/ehu139. Epub 2014 Apr 9.
9
Elevated Incidence of Atrial Fibrillation and Stroke in Patients With Atrial Flutter-A Population-Based Study.
Can J Cardiol. 2018 Jun;34(6):774-783. doi: 10.1016/j.cjca.2018.01.001. Epub 2018 Jan 6.
10
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Am Heart J. 2018 Mar;197:124-132. doi: 10.1016/j.ahj.2017.12.007. Epub 2017 Dec 8.
本文引用的文献
1
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083.
2
Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation.
Circulation. 2012 Oct 30;126(18):2200-7. doi: 10.1161/CIRCULATIONAHA.112.109330. Epub 2012 Sep 26.
3
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Eur Heart J. 2012 Nov;33(22):2821-30. doi: 10.1093/eurheartj/ehs274. Epub 2012 Aug 29.
4
New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.
Drugs. 2012 Sep 10;72(13):1739-53. doi: 10.2165/11635730-000000000-00000.
5
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.
6
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
N Engl J Med. 2012 Aug 16;367(7):625-35. doi: 10.1056/NEJMoa1105594.
7
Impact of impaired renal function and metabolic syndrome on the recurrence of atrial fibrillation after catheter ablation: a long term follow-up.
Pacing Clin Electrophysiol. 2012 May;35(5):532-43. doi: 10.1111/j.1540-8159.2012.03350.x. Epub 2012 Mar 16.
8
Renal function after catheter ablation of atrial fibrillation.
Circulation. 2011 Nov 29;124(22):2380-7. doi: 10.1161/CIRCULATIONAHA.111.047266. Epub 2011 Oct 31.
9
Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation.
Circ J. 2011;75(10):2326-32. doi: 10.1253/circj.cj-11-0178. Epub 2011 Jul 20.
10
Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.
J Am Coll Cardiol. 2011 Mar 22;57(12):1339-48. doi: 10.1016/j.jacc.2010.12.013.
Zotero 插件